BACKGROUND AND OBJECTIVE: To review clinical and structural outcomes of ocriplasmin for treatment of stage 2 macular holes. PATIENTS AND METHODS: A retrospective review of the first patients with stage 2 macular holes to be treated with ocriplasmin at Massachusetts Eye and Ear Infirmary. All patients were imaged with spectral-domain optical coherence tomography (SD-OCT). RESULTS: Eight patients with stage 2 macular holes received a single injection of 125 μg of ocriplasmin. One patient (12.5%) demonstrated macular hole closure. The posterior hyaloid separated from the macula in six eyes (75%). All seven holes that remained open showed enlargement in hole diameters (narrowest, apical, and basal) at 1 week and 1 month. All seven were successfully closed with surgery. Ellipsoid zone disruptions were observed by OCT in four eyes (50%) and persisted throughout follow-up (more than 6 months on average). CONCLUSION: In early clinical results, the authors found a lower macular hole closure rate with ocriplasmin than previously reported. Enlargement was observed in all holes that failed to close with ocriplasmin. The authors found ellipsoid zone disruptions that persisted through 6 months of follow-up after ocriplasmin injection. Further work is needed to investigate the cause for these ellipsoid zone changes. Copyright 2014, SLACK Incorporated.
BACKGROUND AND OBJECTIVE: To review clinical and structural outcomes of ocriplasmin for treatment of stage 2 macular holes. PATIENTS AND METHODS: A retrospective review of the first patients with stage 2 macular holes to be treated with ocriplasmin at Massachusetts Eye and Ear Infirmary. All patients were imaged with spectral-domain optical coherence tomography (SD-OCT). RESULTS: Eight patients with stage 2 macular holes received a single injection of 125 μg of ocriplasmin. One patient (12.5%) demonstrated macular hole closure. The posterior hyaloid separated from the macula in six eyes (75%). All seven holes that remained open showed enlargement in hole diameters (narrowest, apical, and basal) at 1 week and 1 month. All seven were successfully closed with surgery. Ellipsoid zone disruptions were observed by OCT in four eyes (50%) and persisted throughout follow-up (more than 6 months on average). CONCLUSION: In early clinical results, the authors found a lower macular hole closure rate with ocriplasmin than previously reported. Enlargement was observed in all holes that failed to close with ocriplasmin. The authors found ellipsoid zone disruptions that persisted through 6 months of follow-up after ocriplasmin injection. Further work is needed to investigate the cause for these ellipsoid zone changes. Copyright 2014, SLACK Incorporated.
Authors: Peter Stalmans; Matthew S Benz; Arnd Gandorfer; Anselm Kampik; Aniz Girach; Stephen Pakola; Julia A Haller Journal: N Engl J Med Date: 2012-08-16 Impact factor: 91.245
Authors: Rishi P Singh; Ang Li; Rumneek Bedi; Sunil Srivastava; Jonathan E Sears; Justis P Ehlers; Andrew P Schachat; Peter K Kaiser Journal: Br J Ophthalmol Date: 2013-12-19 Impact factor: 4.638
Authors: D H W Steel; C Parkes; V T Papastavrou; P J Avery; I A El-Ghrably; M S Habib; M T Sandinha; J Smith; K P Stannard; D Vaideanu-Collins; R J Hillier Journal: Eye (Lond) Date: 2016-03-11 Impact factor: 3.775
Authors: Haifa A Madi; Richard J Haynes; Diana Depla; Morten D de la Cour; Sarit Lesnik-Oberstein; Mahi M K Muqit; Niall Patton; Nick Price; David H W Steel Journal: Graefes Arch Clin Exp Ophthalmol Date: 2016-06-08 Impact factor: 3.117